Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
2023年11月7日 - 10:00PM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical
company focused on transforming medicines to transform lives,
announced today that members of management will participate in the
following upcoming investor conferences:
- Jefferies London Healthcare Conference:
Fireside chat on Tuesday, November 14 at 5:00 p.m. GMT / 12:00 p.m.
ET.
- Piper Sandler 35th Annual Healthcare
Conference: Fireside chat on Wednesday, November 29 at 11:30 a.m.
ET.
A live webcast of these events, as well as archived recordings,
will be available on Avadel’s Investor Relations website,
investors.avadel.com, for 90 days following each conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a
biopharmaceutical company focused on transforming medicines to
transform lives. Our approach includes applying innovative
solutions to the development of medications that address the
challenges patients face with current treatment options. Avadel’s
commercial product, LUMRYZ™, was approved by the U.S. Food
& Drug Administration (FDA) as the first and only
once-at-bedtime oxybate for the treatment of cataplexy or excessive
daytime sleepiness (EDS) in adults with narcolepsy. For more
information, please visit www.avadel.com.
Investor Contact:Courtney TurianoStern Investor
Relations, Inc.Courtney.Turiano@sternir.com (212) 698-8687
Media Contact:Lesley StanleyReal
Chemistrylestanley@realchemistry.com (609) 273-3162
Avadel Pharmaceuticals (NASDAQ:AVDL)
過去 株価チャート
から 4 2024 まで 5 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
過去 株価チャート
から 5 2023 まで 5 2024